Sakoda Yukimi, Tamada Koji
Nihon Rinsho. 2017 Feb;75(2):281-287.
Chimeric antigen receptor (CAR)-T cell therapy, where patients' own T cells are engi- neered to express receptor that targets antigen found on the surface of cancer cells, delivers outstanding efficacy to treat hematological malignancies. This personalized medicine has been actively explored by researchers in academia and quickly developed for clinical applica- tion by several pharmaceutical/biotech companies. While CAR-T cell therapy is a highly promising technology, many challenges remain to be overcome in targeting solid tumors, in- cluding on-target off-tumor toxicity, inefficient accumulation and survival of CAR-T cells in the immunosuppressive tumor microenvironment. In this review, we briefly describe the cur- rent status, challenges, and future perspectives of CAR-T cell therapy.
嵌合抗原受体（CAR）-T细胞疗法是将患者自身的T细胞进行改造，使其表达能够靶向癌细胞表面抗原的受体，在治疗血液系统恶性肿瘤方面具有显著疗效。这种个性化药物已受到学术界研究人员的积极探索，并被多家制药/生物技术公司迅速开发用于临床应用。虽然CAR-T细胞疗法是一项极具前景的技术，但在靶向实体瘤方面仍有许多挑战有待克服，包括脱靶效应、CAR-T细胞在免疫抑制性肿瘤微环境中的低效聚集和存活。在这篇综述中，我们简要描述了CAR-T细胞疗法的现状、挑战和未来前景。
